Omeros Corporation

    Jurisdiction
    United States
    LEI
    549300CJWLXX2MXVVV71
    ISIN
    US6821431029 (OMER)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    49 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €353.50K
    Gross margin
    -48.5%
    EBIT
    -€118.74M
    EBIT margin
    -33,589.8%
    Net income
    -€105.08M
    Net margin
    -29,726.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €98.46M +27,752.6% -€20.77M -80.2%
    €172.96M +75.7% €19.99M -196.2%
    €406.06M +134.8% €186.88M +835.0%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 15, 2024

    Add to watchlist

    Notifications